Expert Review of Anticancer Therapy

Papers
(The H4-Index of Expert Review of Anticancer Therapy is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Prognostic impact of renin-angiotensin system inhibitors in patients with ovarian cancer: a meta-analysis of real-world evidence88
Clinical characteristics and outcomes among patients with subcutaneous panniculitis-like T-cell lymphoma74
An evaluation of nivolumab plus gemcitabine and cisplatin in the treatment of advanced urothelial carcinoma56
Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?47
Nanotechnology meets liver cancer: liposomal immunotherapy strategies for hepatocellular carcinoma46
Prevailing challenges in personalized treatment for metastatic renal cell carcinoma: a narrative review41
Barriers to the use of brachytherapy for treatment of cervical cancer and prostate cancer in low- and middle-income countries39
Effect of steroid therapy on survival in patients with metastatic solid tumors experiencing immune-related adverse events33
PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects29
Oral decitabine and cedazuridine for the treatment of myelodysplastic syndromes: an integrated review of clinical, economic and patient-centered evidence23
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review22
Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis21
Current status and novel insights into the role of metastasectomy in the era of immunotherapy21
Palbociclib in endocrine-resistant metastatic breast cancer: real-world outcomes20
Importance of radiation-related cognitive decline in older adults who receive cranial radiation19
Current management of familial adenomatous polyposis18
Prognostic and clinicopathological value of myeloid-derived suppressor cells in lung cancer: a comprehensive systematic review and meta-analysis17
0.24980187416077